Gabutti Giovanni, Trucchi Cecilia, Conversano Michele, Zivelonghi Giambattista, Zoppi Giorgio
Department of Prevention, O.U. Hygiene and Public Health, LHU 4 "Chiavarese"-Liguria Region, Corso Dante 163, Chiavari, 16043 Genoa, Italy.
Department of Health Sciences, University of Genova, Via Pastore 1, 16132 Genoa, Italy.
Biomed Res Int. 2014;2014:541319. doi: 10.1155/2014/541319. Epub 2014 Feb 11.
The need for boosters for tetanus, diphtheria, pertussis, and polio, starting from preschool age, is related to the waning immune protection conferred by vaccination, the elimination/reduction of natural boosters due to large-scale immunization programs, and the possibility of reintroduction of wild agents from endemic areas. Taking into account the relevance of safety/tolerability in the compliance with vaccination among the population, it have been assessed whether today enough scientific evidences are available to support the use of dTap-IPV booster in preschool age. The review of the literature was conducted using the PubMed search engine. A total of 41 works has been selected; besides, the documentation produced by the World Health Organization, the European Centre for Disease Control, and the Italian Ministry of Health has been consulted. Many recent papers confirm the opportunity to use a low antigenic dose vaccine starting from 4 to 6 years of age. There is also evidence that 10 years after immunization the rate of seroprotected subjects against diphtheria does not differ significantly between those vaccinated with paediatric dose (DTaP) or reduced dose (dTaP or dTap) product. The dTpa vaccine is highly immunogenic for diphtheria toxoids regardless of prior vaccination history (2 + 1 and 3 + 1 schedules).
从学龄前开始就需要接种破伤风、白喉、百日咳和脊髓灰质炎加强疫苗,这与疫苗接种所提供的免疫保护减弱、大规模免疫规划导致自然加强因素的消除/减少以及从流行地区重新引入野生病原体的可能性有关。考虑到安全性/耐受性在人群疫苗接种依从性中的相关性,评估了目前是否有足够的科学证据支持在学龄前使用白百破-灭活脊髓灰质炎疫苗加强剂。使用PubMed搜索引擎对文献进行了综述。共筛选出41篇研究;此外,还查阅了世界卫生组织、欧洲疾病控制中心和意大利卫生部发布的文件。许多近期论文证实了从4至6岁开始使用低抗原剂量疫苗的合理性。也有证据表明,免疫接种10年后,接种儿童剂量(DTaP)或减量(dTaP或dTap)产品的人群中,对白喉具有血清保护作用的受试者比例没有显著差异。无论既往接种史如何(2+1和3+1接种程序),dTpa疫苗对白喉类毒素都具有高度免疫原性。